IAM
TBPH icon

Iridian Asset Management’s Theravance Biopharma TBPH Stock Holding History

Iridian Asset Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,449,791
Closed -$33.4M – 99
2014
Q3 		$33.4M Sell
1,449,791
-620,892
-30% -$18M 0.34% 44
2014
Q2 		$66M Buy
+2,070,683
New +$62.3M 0.68% 41

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FAM
Foundation Asset Management White Plains, New York $116M AUM 31.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Iridian Asset Management's TBPH Position: Q4 2014 in Review

Iridian Asset Management sold out of Theravance Biopharma (TBPH) in Q4 2014, closing a stake of 1,449,791 shares — an estimated $33.4M sold.

Iridian Asset Management first reported a position in TBPH in Q2 2014 and held it in 2 quarters. The position peaked at $66M in Q2 2014. 93 funds tracked by Wall St. Rank hold TBPH as of Q4 2014.

  • Iridian Asset Management reported no remaining Theravance Biopharma position as of Q4 2014 after selling out during the quarter.
  • Iridian Asset Management sold 1,449,791 Theravance Biopharma shares in Q4 2014, an estimated $33.4M.
  • Iridian Asset Management first reported a position in Theravance Biopharma in Q2 2014 and held it in 2 quarters.
  • Iridian Asset Management's Theravance Biopharma position peaked at $66M in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2014.

Based on Iridian Asset Management's 13F filing for Q4 2014, filed 10 Feb 2015.